Immunovant
Tracked across 1 events · 16 articles · First seen Apr 02, 2026 · Last active May 14, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Immunovant's batoclimab Phase 3 studies failed to meet their primary endpoint for thyroid eye disease, which is a significant setback for the company.
Apr 02, 2026 · 16 articles
ERGEN INTELLIGENCE
Track Immunovant live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard